AR and prostate carcinoma: CBPD-409 also exhibited superior cytotoxicity when compared with other published p300/CBP degraders, bromodomain inhibitors or HAT domain inhibitors in AR-positive prostate cancer cell lines (Fig. 5c and Extended Data Fig. 8e).